Market Cap | 4.12M | P/E | - | EPS this Y | 66.20% | Ern Qtrly Grth | - |
Income | -13.16M | Forward P/E | -0.41 | EPS next Y | 17.80% | 50D Avg Chg | -1.00% |
Sales | 5.33M | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -52.00% |
Dividend | N/A | Price/Book | 0.22 | EPS next 5Y | 14.96% | 52W High Chg | -90.00% |
Recommedations | 2.00 | Quick Ratio | 3.39 | Shares Outstanding | 1.36M | 52W Low Chg | 38.00% |
Insider Own | 2.60% | ROA | -34.50% | Shares Float | 1.14M | Beta | 0.61 |
Inst Own | 20.53% | ROE | -78.36% | Shares Shorted/Prior | 3.67K/4.14K | Price | 4.34 |
Gross Margin | 20.39% | Profit Margin | -262.31% | Avg. Volume | 46,429 | Target Price | 11.00 |
Oper. Margin | -240.26% | Earnings Date | May 9 | Volume | 14,440 | Change | 0.70% |
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
HC Wainwright & Co. | Buy | Apr 5, 24 |
HC Wainwright & Co. | Buy | Aug 28, 23 |
HC Wainwright & Co. | Buy | Jul 24, 23 |
HC Wainwright & Co. | Buy | Jun 5, 23 |
HC Wainwright & Co. | Buy | Apr 14, 23 |